Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
180 studies found for:    "Anemia, Refractory, with Excess of Blasts"
Show Display Options
Rank Status Study
1 Active, not recruiting Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Conditions: Acute Lymphoid Leukemia;   Acute Myeloid Leukemia;   Anemia, Refractory, With Excess of Blasts;   Solid Tumors
Intervention: Drug: brentuximab vedotin
2 Completed Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: alvocidib;   Drug: vorinostat
3 Completed Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Disorders;   Anemia, Refractory, With Excess of Blasts
Intervention: Drug: Hum-195/rGel
4 Active, not recruiting Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Radiation: iodine I 131 monoclonal antibody BC8;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
5 Active, not recruiting Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Vorinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
6 Completed Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: becatecarin;   Other: laboratory biomarker analysis
7 Completed XK469R in Treating Patients With Refractory Hematologic Cancer
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: R(+)XK469;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Completed Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Interventions: Biological: PR1 leukemia peptide vaccine;   Drug: Montanide ISA 51 VG;   Biological: sargramostim;   Other: laboratory biomarker analysis
9 Recruiting Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Meningeal Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: fludarabine phosphate;   Drug: treosulfan;   Radiation: total-body irradiation;   Procedure: umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
10 Completed Thalidomide in Treating Patients With Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
11 Completed Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Conditions: Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Drug: therapeutic hydrocortisone;   Procedure: allogeneic bone marrow transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Biological: filgrastim;   Drug: cytarabine;   Drug: idarubicin;   Drug: dexamethasone;   Drug: thioguanine;   Drug: etoposide;   Drug: methotrexate;   Drug: cyclophosphamide;   Biological: aldesleukin;   Drug: busulfan
12 Active, not recruiting A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: ex-vivo umbilical cord blood expansion;   Procedure: double-unit umbilical cord blood transplantation;   Procedure: biopsy;   Other: immunologic technique;   Other: diagnostic laboratory biomarker analysis
13 Active, not recruiting Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Procedure: umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
14 Completed CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
15 Recruiting Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation;   Other: laboratory biomarker analysis
16 Completed SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Conditions: Acute Undifferentiated Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: ispinesib;   Other: laboratory biomarker analysis;   Other: pharmacological study
17 Completed Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Conditions: Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation
Interventions: Drug: liposomal daunorubicin citrate;   Drug: semaxanib;   Other: laboratory biomarker analysis
18 Recruiting Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Fanconi Anemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Intervention: Other: laboratory biomarker analysis
19 Completed BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Conditions: Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: BMS-214662;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Completed Tipifarnib in Treating Patients With Myelodysplastic Syndromes
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia
Interventions: Drug: tipifarnib;   Other: laboratory biomarker analysis;   Other: pharmacological study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years